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AbstrAct
Objective
To study whether a high volume injection without 
corticosteroids improves clinical outcome in addition 
to usual care for adults with chronic midportion 
Achilles tendinopathy.
Design
Patient and assessor blinded, placebo controlled 
randomised clinical trial.
setting
Sports medicine department of a large district general 
hospital, the Netherlands.
ParticiPants
80 adults (aged 18-70 years) with clinically diagnosed 
chronic midportion Achilles tendinopathy and 
neovascularisation on ultrasonography. 39 were 
randomised to a high volume injection without 
corticosteroids and 41 to placebo.
interventiOns
Participants were instructed to perform an exercise 
programme for 24 weeks (usual care) combined 
with one 50 mL high volume injection of saline and 
lidocaine (intervention group) or one 2 mL placebo 
injection of saline and lidocaine (placebo group) at 
baseline.
Main OutcOMe Measures
Primary outcome was pain and function assessed 
using the validated Victorian Institute of Sports 
Assessment-Achilles (VISA-A) questionnaire at 24 
weeks (analysed using a generalised estimation 
equations model). Secondary outcomes were 
patient satisfaction, return to sport, degree of 
ultrasonographic Doppler flow, visual analogue 
scale on 10 hop test, power and flexibility of the 
gastrocnemius and soleus muscles, pain detect 
questionnaire for neuropathic pain, and pain coping 
inventory. Participants were evaluated at baseline and 
at 2, 6, 12, and 24 weeks.
results
Only one participant (1%) was lost to follow-up. The 
estimated mean VISA-A score improved significantly, 
from 40.4 (95% confidence interval 32.0 to 48.7) at 
baseline to 59.1 (50.4 to 67.8) at 24 weeks in the 
high volume injection group and from 36.9 (27.1 to 
46.8) to 58.5 (47.9 to 69.1) in the placebo group. 
The VISA-A score over time did not differ between 
the groups (adjusted between group difference at 24 
weeks 0.5 points, 95% confidence interval −17.8 to 
18.8). No significant between group differences were 
found for patient satisfaction (21/37 (57%) v 19/39 
(49%) patients, P=0.50) and return to desired sport 
(15/29 (52%) v 19/31 (61%) patients active in sports, 
P=0.65) at 24 weeks. None of the other secondary 
outcomes differed between the two groups.
cOnclusiOns
A high volume injection without corticosteroids in 
addition to usual care is not effective for symptom 
reduction in patients with chronic midportion Achilles 
tendinopathy. On the basis of our findings, we cannot 
recommend the use of a high volume injection in this 
patient group.
trial registratiOn
ClinicalTrials.gov NCT02996409
Introduction
Chronic disorders of the Achilles tendon (tendinopathy) 
are a common overuse injury seen in general practice, 
with an incidence rate of 2-3 per 1000 registered 
adult patients.1 Most (74%) of these patients have 
midportion Achilles tendinopathy.2 Runners are most 
at risk of developing symptoms, with a lifetime risk of 
52%.3 The initial treatment of Achilles tendinopathy 
is exercise combined with load management.4 Despite 
initiation of treatments, two thirds of patients continue 
to have symptoms at one year follow-up.5 At 10 
years follow-up, about a quarter of patients still have 
symptoms.5 6 About one third of these non-responders 
eventually require surgery.4 7 Therefore, effective 
conservative treatment options are necessary to 
improve the outcome of patients with chronic Achilles 
tendinopathy who fail to respond to initial exercise 
treatment.
The formation of blood vessels (neovascularisation) 
around and within the tendon is one of the features 
of chronic Achilles tendinopathy. Neovascularisation 
can be identified in 50-100% of patients with 
tendon symptoms using Doppler ultrasonography, 
compared with 0-30% in asymptomatic patients.8-12 
The infiltration of nerve structures alongside this 
neovascularisation has been suggested to play a role in 
the chronicity of pain from Achilles tendinopathy.13 14 
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WhAt Is AlreAdy knoWn on thIs topIc
Achilles tendinopathy is common and symptoms are often chronic
About 25-50% of patients show no improvement one year after conservative 
interventions
Neovascularisation, along with nerve infiltration, is one of the features in chronic 
symptoms; a high volume injection has been developed to obliterate these 
structures and is gaining popularity, yet robustly designed studies are lacking
WhAt thIs study Adds
A high volume injection without corticosteroids in patients with chronic 
midportion Achilles tendinopathy results in an initial decreased ultrasonographic 
Doppler flow
The high volume injection was not effective in reducing symptoms
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A large study showed an association between the 
degree of ultrasonographic Doppler flow and patient 
reported severity of symptoms.8
Consequently, treatments have been developed to 
target neovascularisation. A novel technique is high 
volume injection, in which a large amount of fluid is 
injected into the area surrounding the tendon with the 
aim of obliterating peritendinous and intratendinous 
neovascularisation from high mechanical pressure.14 
Current debate is on the addition of corticosteroids 
to the injection mixture. Recent evidence shows 
that a high volume injection with corticosteroids is 
associated with superior short term improvement at 
6-12 weeks compared with a high volume injection 
without corticosteroids, but intermediate term effects 
are similar.15 Several cohort studies and one small 
randomised controlled trial found that a high volume 
injection (both with and without corticosteroids) 
resulted in decreased pain and improved function in 
the short term (6-12 weeks).14 16-19 As a consequence, 
this treatment is increasingly being used in the 
clinical setting although its effectiveness has not been 
tested in a large well designed study. In this study, 
we compared the effect of a high volume injection 
without corticosteroids with a placebo injection (both 
combined with an exercise programme) on pain and 
functional outcome at 24 weeks in patients with 
chronic midportion Achilles tendinopathy.
Methods
study design and participants
This study was conducted as a stratified, patient and 
assessor blinded, placebo controlled randomised 
clinical trial, with 1:1 allocation ratio, at the sports 
medicine department of a large district general 
hospital (Haaglanden Medical Centre, The Hague, 
Netherlands). The study was announced through 
letters to healthcare professionals, presentations 
at national conferences, and information on a 
national sports medicine platform. Potentially 
eligible participants were identified from referrals 
by healthcare providers and self-referrals, thereby 
comprising a mix of patients with and without primary 
care from healthcare providers. The coordinating 
researcher (AvdV) provided participants with detailed 
information on the study. Participants were screened 
for eligibility by telephone and online (using a pain 
map). A sports medicine physician (RvO) evaluated 
potentially eligible participants for inclusion at a 
booked appointment. Participants provided written 
informed consent before inclusion.
We included patients if they were aged 18-70 
years, had a painful swelling of the Achilles tendon 
2-7 cm proximal to the insertion on the calcaneus, 
had had symptoms for at least two months, had an 
unsatisfactory outcome after a six week exercise 
programme, and had detectable Doppler flow. When 
symptoms were bilateral, participants selected the 
most severely affected tendon for treatment. All the 
participants performed a minimum of six weeks of 
exercise treatment before inclusion.
Patients were excluded if they had a history of an 
Achilles tendon rupture or surgery; were unable to 
perform the exercise programme, were engaged in 
concomitant treatment programmes, had sural nerve 
disease, had recent drug use (within two years) with 
putative effect on symptoms and tendon healing 
(quinolone antibiotics, corticosteroids), were suspected 
of having other musculoskeletal disorders clinically 
(insertional Achilles tendinopathy, plantar flexor 
tenosynovitis, peroneal subluxation, inflammatory 
internal disorders, or quinolone, corticosteroid, or 
statin induced tendinopathy), had a medical condition 
that would affect the safety of the participant when 
using the injection (eg, peripheral vascular disease, 
use of anticoagulant drugs, allergy for lidocaine), or 
were pregnant.
Procedures
One researcher (AvdV) prepared five 10 mL syringes 
(total volume 50 mL) for each patient. These syringes 
contained a mixture of 8 mL 0.9% sodium chloride 
solution (saline) and 2 mL 1% lidocaine (B Braun; 
Melsungen, Germany). Before and directly after 
injection, we used a Pro Focus Type 2202 (BK Medical; 
Herlev, Denmark) with a 5-12 MHz linear probe 
type 8811 to perform ultrasonography. The area of 
maximum Doppler flow was detected using power 
Doppler ultrasonography with predefined settings 
determined before the start of the study (mechanical 
index 1.28, thermal index 1.2, pulse repetition 
frequency 1.0 kHz, and gain 50%).20 We recorded 
the presence of intratendinous and peritendinous 
Doppler flow immediately after the injection. A 
blinded observer evaluated the presence of Doppler 
flow on these records to verify the success of the 
procedure after the trial had ended. These results 
had no consequences on the injection procedure—
that is, no second injection was performed if Doppler 
flow was still present after the high volume injection. 
Complications and co-interventions were registered at 
each visit. All participants received daily compliance 
logs to complete for evaluation of adherence to the 
exercise programme. The participants were asked to 
upload these logs digitally every week. Reminders 
were sent to non-responders after five days.
randomisation and masking
We used stratification for pre-injury activity level, 
since this could be a confounder for the primary 
outcome of pain and functional activity level using 
the Victorian Institute of Sports Assessment-Achilles 
(VISA-A) questionnaire.21 Stratification was conducted 
using the ankle activity score, which quantifies ankle 
related activity based on type and level of activities.22 
Participants with an ankle activity score of 4 points 
or more were considered to be active and those with 
a score of 3 points or less were considered to be 
sedentary.23 Participants were randomised using a 
computer generated randomisation list (Microsoft 
Access; Redmond, WA). To ensure a balance between 
the number of participants in each treatment group, 
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we performed block randomisation, with a variable 
block size of 4-10. To ensure blinding of the outcome 
assessor (AV), a secretary performed the randomisation 
who was independent of the researchers responsi-
ble for enrolment or the assessment of outcome 
measures. After randomisation, an unblinded sports 
medicine physician (RvO) who was not involved in 
the assessment of outcome measures carried out the 
allocated injection treatment. The participants were 
blinded to their assigned treatment, as they could 
not see the injection procedure. All the participants 
completed a short questionnaire immediately after the 
injection to check whether the blinding procedure was 
successful (which type of injection do you think you 
have received (high volume injection or placebo)?) and 
to assess the amount of pain (visual analogue scale 
0-100, using a 100 mm line) during the procedure.
interventions
High volume injection—Participants were placed in 
the prone position on the examination table with 
the affected ankle hanging over the edge. To ensure 
blinding, participants were asked not to turn their head 
during the injection procedure. The sports medicine 
physician inserted a 21 gauge and 40 mm long needle 
from the medial side of the ankle between the anterior 
aspect of the Achilles tendon and the anteriorly 
located Kager’s fat pad. The needle was attached to a 
connecting tube of 30 cm with Luer taper (Argon MC; 
Frisco, TX) to attach the syringes on the other side. 
The first syringe with the saline and lidocaine mixture 
(10 mL) was injected at the area of maximum Doppler 
flow. The following four syringes (10 mL each) were 
injected 1-2 cm proximal, distal, medial, and lateral, 
with coverage of the whole width of the tendon under 
real-time ultrasonography. The injection technique 
was identical to that described previously.14 Materials 
were stored in an opaque box to ensure blinding of 
the participants after the injection. The participants 
remained prone on the examination table for 5-7 
minutes after the procedure.
Placebo injection—The placebo injection involved 
a similar technique, mixture, and duration as for the 
high volume injection. The only difference was the 
amount of injected fluid. Except for the third syringe, 
only 0.5 mL of each of the five syringes was injected at 
the different injection locations in the placebo group. 
The third syringe was attached to the connecting tube 
and the needle was localised at the injection site, but 
no fluid was injected. Therefore, 2 mL of the saline 
and lidocaine mixture was injected in total. To ensure 
blinding, the participants were unaware of the amount 
of injected fluid and type of procedure used for either 
treatment group. The participants were advised to 
refrain from strenuous walks and sports activities 
during the first 24 hours after the injection.
exercise programme
The blinded outcome assessor (AV) instructed all the 
participants to perform a daily calf muscle exercise 
programme using detailed written information and 
videos. The exercise programme was based on an 
existing protocol, consisting of three consecutive 
phases: isometric exercises, concentric exercises, and 
eccentric exercises.24 25 The participants were asked to 
start the next phase if exercises could be performed for 
one week with acceptable symptoms (visual analogue 
scale score of ≤3/10 in activities and in daily life). 
If eccentric exercises could be performed without 
problems for at least one week, the participants 
continued with the return to sports module. This 
module consisted of four phases: simple plyometric 
exercises, fast plyometric exercises, a gradual increase 
in running, and interval training (if necessary for the 
type of sports). Web appendix 1 provides detailed 
information on the exercise programme and return to 
sport module.
All the participants were advised to refrain from 
weightbearing sporting activities for at least five weeks. 
The exercises and activities should be performed with 
only mild pain (maximum score of 3 on a scale from 
0 to 10, with 0 indicating no pain and 10 maximum 
pain), and the participants were advised to decrease 
the activity level when the pain increased to more 
than 3 points during or after the activity or when 
morning stiffness increased one day after the activity 
compared with the previous days.24 The participants 
were then instructed to decrease their activity until 
symptoms had returned to an acceptable level. They 
were discouraged from using other treatments for their 
Achilles tendinopathy.
Outcome measures
The primary outcome measure was the Dutch version 
of the VISA-A questionnaire.26 This validated and 
disease specific questionnaire quantifies pain and 
activity levels,27 with scores ranging from 0 to 100: 
100 indicates no pain with full activity level, with the 
score decreasing with increasing severity of symptoms. 
Secondary outcomes were patient satisfaction, return 
to sport, degree of ultrasonographic Doppler flow, 
visual analogue scale on 10 hop test, power and 
flexibility of the gastrocnemius and soleus muscles, 
pain detect questionnaire, and pain coping inventory. 
Patient satisfaction was scored as moderate or poor 
or as excellent or good. Return to sport was scored as 
no return to the desired sport or return to the desired 
sport (regardless of reaching pre-injury level). All 
outcome measures were assessed at baseline (before 
intervention) and at 2, 6, 12, and 24 weeks.
statistical analysis
Our sample size calculation showed that 40 
participants were required in each group to detect 
a difference of 12 points on the VISA-A score (power 
0.80, two sided significance level of 0.05, SD 18, 
and accounting for a 10% loss to follow-up).23 28 29 A 
researcher (AvdV) performed the statistical analyses 
under the supervision of a biomedical statistician 
(JW); both were blinded to the allocated treatment. 
Data were analysed on an intention-to-treat basis 
using SPSS 25.0.0.1 (SPSS, Chicago, IL). Normality 
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of the data was checked visually with Q-Q plots and 
statistically using the Shapiro-Wilk test. Between group 
differences for the primary outcome were analysed 
using a generalised estimation equations model. To 
test whether the time course of the VISA-A score was 
different between groups we added the interaction 
term of treatment group×time point. Adjustments were 
made for the four predefined baseline variables of 
age, sex, body mass index, and duration of symptoms. 
Additionally, we adjusted for the stratification factor 
(ankle activity score).30 Outcomes of the generalised 
estimation equations model are presented as estimated 
means, unless otherwise stated. The same method was 
used to evaluate most of the secondary outcomes (see 
web appendix 2). A Fisher’s exact test was used to 
evaluate only patient satisfaction, return to sport, and 
the patient acceptable symptom scale. The outcomes to 
evaluate the success of the procedures were analysed 
using a Fisher’s exact test or χ2 test (categorical 
outcomes) or unpaired t test or Mann-Whitney U test 
(continuous outcomes). We considered differences of 
P<0.05 to be statistically significant. Missing data were 
not imputed, but we would have carried out sensitivity 
analyses if missing data exceeded 5%.
Patient and public involvement
Patients were not involved in defining the research 
question. Two patients participated in a pilot test 
round to evaluate the impact of the placebo and high 
volume injection procedure. Patients were not involved 
in other aspects of the study design. After completion 
of the trial, all trial participants were contacted to 
evaluate relevant outcome measures and the burden of 
participation to improve future trials. Five participants 
took part in a patient meeting to discuss these 
items. Study results will be disseminated to the trial 
participants by email or letter.
results
From December 2016 to January 2019, 185 patients 
with posterior ankle pain were screened for eligibility. 
After exclusions 80 participants were included in the 
study and randomised to either a high volume injection 
without corticosteroids or a saline injection (placebo 
group). At the 24 week endpoint, only one participant 
was lost to follow-up (1%). Figure 1 shows the flow 
of participants through the trial. No differences in 
baseline characteristics were found between the 
groups, except for the presence of bilateral symptoms 
(table 1). A higher proportion of participants in the 
high volume injection group had bilateral symptoms 
(17/39 (44%) v 11/41 (27%)). An additional analysis 
using a generalised estimation equations model was 
done to correct for the variable unilateral or bilateral 
symptoms.
Outcome measures
VISA-A score—In the high volume injection group the 
estimated mean VISA-A score improved from 40.4 
(95% confidence interval 32.0 to 48.7) at baseline to 
59.1 (50.4 to 67.8) at 24 weeks and in the placebo 
group from 36.9 (27.1 to 46.8) to 58.5 (47.9 to 69.1). 
The interaction term treatment group×time point was 
not statistically significant (P=0.42), meaning that 
the VISA-A score did not differ over time between the 
groups. The adjusted between group difference in 
VISA-A score at 24 weeks was 0.5 (95% confidence 
interval −17.8 to 18.8) in favour of the high volume 
injection group (table 2). Improvement in VISA-A 
score was not significant at two weeks for either 
group. VISA-A scores improved significantly in both 
groups at six weeks (P=0.05) and at 12 and 24 weeks 
(P<0.01). Figure 2 presents the raw changes in VISA-A 
scores. In the sensitivity analysis using the additional 
generalised estimation equations model to correct 
for unilateral or bilateral symptoms, the results for 
the primary outcome (interaction term treatment 
group×time point, P=0.44) remained unchanged.
Patient satisfaction—No significant difference was 
found in patient satisfaction between the treatment 
groups at 24 weeks (P=0.50). In the high volume 
injection group, 21/37 patients (57%) reported an 
excellent or good outcome compared with 19/39 
(49%) in the placebo group.
Return to desired sport—No significant difference 
was found for return to the desired sport at 24 
weeks (P=0.65). In the high volume injection group, 
15/29 (52%) patients returned to their desired sport 
compared with 19/31 (61%) in the placebo group. Of 
these participants, only 4/29 (14%) returned to their 
pre-injury level in the high volume injection group and 
5/31 (16%) in the placebo group.
Web appendix 2 shows the results of the other 
secondary outcome measures. No significant between 
group differences were found for any of these outcome 
measures.
success of procedures
Success of injection procedure on Doppler flow—In 
participants with intratendinous Doppler flow before 
the injection procedure (n=33 in the high volume 
injection group and n=37 in the control group; table 
1), Doppler flow was no longer detectable inside 
the Achilles tendon in 26/33 patients (79%) in the 
high volume injection group compared with 11/37 
patients (30%) in the control group (P<0.001). The 
disappearance of Doppler flow after the high volume 
injection did not appear to influence the course of the 
VISA-A score over time compared with the presence of 
Doppler flow after the high volume injection (P=0.99), 
as explained in detail in web appendix 4.
Success of patient blinding—In the high volume 
injection group, 25/39 patients (64%) correctly 
thought they had received the high volume injection. 
In the placebo group, 22/41 patients (54%) correctly 
thought they had received the placebo injection 
(P=0.36).
Complications and pain during injection procedure—
No complications (infections, haematomas, or tendon 
ruptures) were reported during the study period. The 
median pain score (visual analogue scale score 0-10) 
during the injection procedure was 6.0 (interquartile 
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Patients screened for eligibility
Excluded
Did not perform exercise treatment
Insertional tendinopathy
No longer willing to participate
Use of prednisone or anticoagulants
No further contact possible
Travel time
Chose another treatment
Symptoms currently not restrictive
<18 or >70 years old
Previous tendon rupture or ankle surgery
Autoinflammatory disease
Inferior heel pain
Not able to perform exercise treatment
20
18
11
9
8
7
6
6
5
5
4
2
1
Randomised to high volume
injection and participated in
gradually increasing training programme
Received intervention as assigned39
Randomised to placebo
injection and participated in
gradually increasing training programme
Received intervention as assigned41
Clinical assessment at research location
Assessed at 2 weeks
185
102
Excluded
Retrocalcaneal bursitis on ultrasonography
Combined insertional and midportional
  tendinopathy
Fear of injection
1
1
1
41
41
Assessed at 24 weeks
41
Included in primary analysis
38
Assessed at 2 weeks
Not contactable
Unable to visit due to other medical condition
1
1
37
Assessed at 6 weeks
Not contactable
Unable to visit due to other medical condition
Discontinued due to unsatisfactory outcome
Family circumstances
2
1
1
1
34
Assessed at 6 weeks
Work related travel1
40
Assessed at 12 weeks
Not contactable
Unable to visit due to other medical condition
Discontinued due to unsatisfactory outcome
1
1
1
36
Included in primary analysis
41
Assessed at 24 weeks
Discontinued due to unsatisfactory outcome1
38
Assessed at 12 weeks
Not contactable1
40
83
Randomised
80
39
3
Fig 1 | Flow of participants through study
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range 5.0-8.0) for the high volume injection group and 
5.0 (2.0-7.0) for the placebo group (P=0.10).
Adherence—80% of participants (1536 out of 
1920 questionnaires) completed the weekly online 
questionnaires to evaluate adherence to exercise 
treatment. The median percentage of performed 
exercises (compared with the amount of prescribed 
exercises) was 76% (interquartile range 46-100%) in 
the high volume injection group and 72% (43-100%) 
in the placebo group (P=0.17).
Co-interventions—The use of 12 co-interventions 
(eg, foot orthoses, manual treatment, and sports 
massage) was reported in 12 patients (31%) in the 
high volume intervention group compared with nine 
co-interventions in six patients (15%) in the placebo 
group (P=0.30).
discussion
In our patient and assessor blinded, placebo controlled 
randomised clinical trial we found that a high volume 
injection without corticosteroids has no added value 
to an exercise programme in patients with chronic 
midportion Achilles tendinopathy. We found no diffe-
rences in patient reported outcomes between the high 
volume injection and a placebo injection. Also, no 
between group differences were found in any of the 
secondary outcome measures, indicating that a high 
volume injection does not have mechanistic effects.
clinical implications
These findings are important and clinically relevant, 
as high volume injections have become increasingly 
popular after several non-blinded case series and 
one cohort study showed an improvement in pain 
during activities at intermediate term follow-up 
(30-52 weeks).14 18 31 These findings exceeded the 
improvement known from eccentric exercises.24 32-34 
As previous high volume injection studies were only 
performed in non-responders to eccentric training, this 
treatment gained even more attention. Surprisingly, 
large improvements (38 points on the VISA-A score) 
after a high volume injection were already seen in 
the short term (three weeks).17 This indicates a rapid 
decrease in symptoms of Achilles tendinopathy when 
a high volume injection is given. A recent blinded 
randomised controlled trial with a small sample size 
(n=19 in each treatment group) confirmed these 
findings, in which patient reported outcomes improved 
significantly more in the high volume injection group 
at the six week follow-up compared with the placebo 
group. This improvement had slightly decreased at 
the 24 week follow-up. Improvement in VISA-A score 
was lower than expected in the placebo group at 24 
weeks, thereby raising the possibility of unsuccessful 
blinding of the participants.16 23 35 36 In our large study, 
we did not find any beneficial effect of the high volume 
injection in either the short term (2 or 6 weeks) or the 
intermediate term (12 or 24 weeks). An important 
difference between our study and previous studies 
investigating high volume injections, is that we did 
not use corticosteroids in the injection mixture. The 
hypothesis is that the saline solution in the injection 
mechanically damages the neovascularisation and 
its adjacent nerves.14 Corticosteroids are discouraged 
as treatment for tendinopathies owing to detrimental 
long term effects and the risk of ruptures to the 
Achilles tendon.37-39 Therefore, we decided not to 
include corticosteroids in the injection mixture. This 
could explain the difference in outcomes between our 
study and previous studies. We hypothesise that a high 
table 1 | baseline characteristics of adults with chronic midportion achilles tendinopathy assigned to a high volume 
injection without corticosteroid or placebo injection. values are numbers (percentages) unless stated otherwise
characteristics High volume injection group (n=39) Placebo injection group (n=41)
Mean (SD) age (years) 46.9 (8.1) 48.9 (9.9)
Men 17 (44) 22 (54)
Mean (SD) body mass index 26.8 (5.7) 27.6 (5.1)
Activity level*:
 Active in sports 31 (79) 33 (80)
 Sedentary 8 (21) 8 (20)
Participation in desired sport (total hours per week) 3.9 (2.0) 4.9 (3.6)
Affected side:
 Unilateral, left/right 11/11 (56) 15/15 (73)
 Bilateral 17 (44) 11 (27)
Median (interquartile range) duration of symptoms (weeks) 64 (17-112) 60 (14-107)
Mean (SD) VISA-A score 44.4 (15.5) 41.0 (16.0)
Interventions at study start:
 None 24 (62) 19 (46)
 Night splint 1 (3) 0 (0)
 Foot orthoses 10 (26) 18 (44)
 Pain killers 1 (3) 4 (10)
 Others 3 (8) 1 (2)
Doppler flow:
 Intratendinous 33 (85) 37 (90)
 Peritendinous 6 (15) 4 (10)
VISA-A=Victorian Institute of Sports Assessment-Achilles.
*Determined using the ankle activity score. Participants who scored ≥4 points were considered to be active in sports (starting from physical work). 
Participants who scored ≤3 points were considered to be sedentary (cycling, equestrian, or less activity). Level of sport and sports participation is only 
presented for the active group.
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volume injection does not have a mechanical pain 
reducing effect but that the short term improvement as 
seen in previous studies might have been related to the 
corticosteroids. The previous randomised controlled 
trial evaluating the high volume injection supports 
this hypothesis, since short term outcome exceeded 
the long term outcome. This is a typical course after 
treatment with a corticosteroid injection.40 In studies 
that did not use corticosteroids in the injection 
mixture, comparable results to ours were seen at 12-24 
weeks.15 19 31 The clinical improvement in symptoms 
of Achilles tendinopathy for both treatment arms in 
our study is similar to that reported in a recent meta-
analysis evaluating the effectiveness of treatment 
using heavy load eccentric calf muscle exercise, and 
in a comparable population included at our research 
centre in which standalone exercise treatment was 
provided.28 41 The difference in the form of exercise 
programmes is not likely to have influenced the results, 
because no evidence suggests that one form of exercise 
training is superior to another.42 Improvement could 
additionally be explained by the placebo effect, patient 
education, load management, and the clinical course 
of the disorder. Our findings indicate that an exercise 
programme, patient education, and load management 
are still beneficial in patients with no previous 
improvement during calf muscle exercise training. 
We would therefore advice all patients to continue an 
exercise programme as the basis of their treatment.
strengths and limitations of this study
The strength of our study is that we performed this 
randomised clinical trial according to the current 
consolidated standards of reporting trials (CONSORT) 
guideline. The patients, outcome assessor, and statis-
tician were all blinded to the intervention, and only 
one participant was lost to follow-up. Despite our 
robust research design, our study also has some 
methodological limitations. Firstly, it was not feasible 
to blind the doctor who performed the injection 
procedure at baseline. As this doctor was not involved 
in the treatment allocation (randomisation), follow-
up of participants, or data analysis, this probably did 
not influence study outcomes. Secondly, the lack of 
a group that only performed an exercise programme 
(without injection) might be regarded as limitation. We 
do not know whether the improvement of symptoms 
over time in both groups is a consequence of the 
exercise programme, a promoted healing response 
after the injection procedure, a placebo effect from the 
injection procedure, or represents the clinical course of 
Achilles tendinopathy. Thirdly, a high volume injection 
is a technically demanding and specific procedure. 
A single sports medicine doctor with extensive 
table 2 | Primary and secondary outcome measures in adults with chronic midportion achilles tendinopathy assigned to a high volume injection 
without corticosteroid or placebo. values are numbers (percentages) unless stated otherwise
Outcome measures High volume injection group (n=39) Placebo injection group (n=41) adjusted between group difference
Primary outcome
Estimated mean (95% CI) VISA-A score at follow-up (weeks)*:
 2 41.4 (33.7 to 49.1) 38.2 (28.3 to 48.1) 3.2 (−11.2 to 17.5)
 6 43.3 (34.6 to 52.0) 46.1 (35.7 to 56.6) −2.8 (−18.9 to 13.3)
 12 50.9 (42.3 to 59.5) 49.6 (39.3 to 60.0) 1.3 (−14.7 to 17.3)
 24 59.1 (50.4 to 67.8) 58.5 (47.9 to 69.1) 0.5 (−17.8 to 18.8)
secondary outcomes
Patient satisfaction†:
 Moderate or poor 16 (43) 20 (51)
 Excellent or good 21 (57) 19 (49)
Return to sport‡: n=29 n=31
 No return to sport 9 (31) 7 (23)
 Returned to sport, but not to desired type 5 (17) 5 (16)
 Returned to desired sport, but not at pre-injury level 11 (38) 14 (45)
 Returned to desired sport at pre-injury level 4 (14) 5 (16)
VISA-A=Victorian Institute of Sports Assessment-Achilles.
*Scores and adjusted between group differences were calculated using a generalised estimation equations model with adjustments for predefined baseline variables: age, sex, body mass index, 
duration of symptoms, and ankle activity score. Positive values favour the high volume injection group. No statistically significant differences were found between the treatment groups at any 
time point.
†For analysis purposes, good or excellent patient satisfaction was dichotomised as “satisfied,” and a poor or moderate satisfaction as “dissatisfied.” Two patients in each group did not return the 
questionnaire in which patient satisfaction was assessed. No statistically significant differences were found between the treatment groups at 24 weeks (P=0.50).
‡Number represents the proportion of participants who were active in sports before the study start (n=31 in the high volume injection group and n=33 in the placebo injection group). Two 
patients in each group did not return the questionnaire in which return to sport was assessed. Return to sport was dichotomised as “no return to desired sport” (no return to sport or return to 
sport, but not in the desired sport) or “return to desired sport” (regardless reaching pre-injury level). No statistically significant differences were found between both treatment groups at 24 weeks 
(P=0.65).
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Fig 2 | between group differences in victorian institute of sports assessment-achilles 
(visa-a) score from baseline in participants treated with a high volume injection 
without corticosteroids or a placebo injection at 2, 6, 12, and 24 weeks. Whiskers 
represent 95% confidence intervals
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experience in injection procedures performed the 
interventions. Test sessions were carried out before the 
start of the study according to instructions provided 
by experts in high volume injections.14 Intratendinous 
Doppler flow disappeared in 79% of the patients in 
the high volume injection group compared with 30% 
in the placebo group, indicating success with the high 
volume injection.
conclusion
In patients with a chronic midportion Achilles 
tendinopathy, a high volume injection without corti-
costeroids did not result in a beneficial effect in 
addition to an exercise programme. On the basis of 
these findings, we cannot recommend the use of a high 
volume injection in this patient group.
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